These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31222765)

  • 1. Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending-dose study.
    Small D; Ferguson-Sells L; Dahdah N; Bonnet D; Landry J; Li B
    Br J Clin Pharmacol; 2019 Oct; 85(10):2302-2309. PubMed ID: 31222765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.
    Ferguson-Sells L; Velez de Mendizabal N; Li B; Small D
    Clin Pharmacokinet; 2022 Feb; 61(2):249-262. PubMed ID: 34379314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension.
    Rehmel J; Ferguson-Sells L; Morse BL; Li B; Dickinson GL
    CPT Pharmacometrics Syst Pharmacol; 2022 Feb; 11(2):173-184. PubMed ID: 34800000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of drugs for pediatric pulmonary hypertension.
    Nakau K; Sugimoto M; Oka H; Kajihama A; Maeda J; Yamagishi H; Kamiyama N; Tasaki Y; Kajino H; Azuma H
    Pediatr Int; 2016 Nov; 58(11):1112-1117. PubMed ID: 27038140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study.
    Beghetti M; Haworth SG; Bonnet D; Barst RJ; Acar P; Fraisse A; Ivy DD; Jais X; Schulze-Neick I; Galiè N; Morganti A; Dingemanse J; Kusic-Pajic A; Berger RM
    Br J Clin Pharmacol; 2009 Dec; 68(6):948-55. PubMed ID: 20002090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
    Vachiéry JL; Galiè N; Barberá JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Blair C; Miller KL; Langley J; Rubin LJ;
    J Heart Lung Transplant; 2019 Feb; 38(2):194-202. PubMed ID: 30522722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment.
    Teymouri Rad R; Dadashzadeh S; Vatanara A; Alavi S; Ghasemian E; Mortazavi SA
    Eur J Pharm Sci; 2019 May; 133():275-286. PubMed ID: 30953751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral drugs used to treat persistent pulmonary hypertension of the newborn.
    Zhang W; Wu YE; Yang XY; Shi J; van den Anker J; Song LL; Zhao W
    Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1295-1308. PubMed ID: 33180564
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
    Wrishko RE; Dingemanse J; Yu A; Darstein C; Phillips DL; Mitchell MI
    J Clin Pharmacol; 2008 May; 48(5):610-8. PubMed ID: 18305126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
    Ried M; Neu R; Lehle K; Großer C; Szöke T; Lang G; Hofmann HS; Hoenicka M
    Interact Cardiovasc Thorac Surg; 2017 Aug; 25(2):254-259. PubMed ID: 28486684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
    Oudiz RJ; Brundage BH; Galiè N; Ghofrani HA; Simonneau G; Botros FT; Chan M; Beardsworth A; Barst RJ;
    J Am Coll Cardiol; 2012 Aug; 60(8):768-74. PubMed ID: 22818063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension.
    Tanaka S; Uchida S; Hakamata A; Miyakawa S; Odagiri K; Inui N; Watanabe H; Namiki N
    Pharmazie; 2020 Jun; 75(6):236-239. PubMed ID: 32539916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.
    Magee AG; Makhecha S; Bentley S
    Expert Opin Drug Saf; 2015 May; 14(5):633-42. PubMed ID: 25746065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 15. Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension.
    Hatano M; Abe K; Koike G; Takahashi T; Tunmer G; Kiely DG
    Int Heart J; 2022; 63(1):99-105. PubMed ID: 35095084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3.
    Berger RMF; Gehin M; Beghetti M; Ivy D; Kusic-Pajic A; Cornelisse P; Grill S; Bonnet D;
    Br J Clin Pharmacol; 2017 Aug; 83(8):1734-1744. PubMed ID: 28213957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial hypertension: a sub-group analysis based on Japan post-marketing surveillance.
    Yamazaki H; Kobayashi N; Taketsuna M; Tajima K; Suzuki N; Murakami M
    Curr Med Res Opin; 2017 Dec; 33(12):2241-2249. PubMed ID: 28699846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma concentrations of tadalafil in children with pulmonary arterial hypertension.
    Kohno H; Ichida F; Hirono K; Ozawa S; Yoshimura N; Nakamura T; Akita C; Ishida K; Taguchi M
    Ther Drug Monit; 2014 Oct; 36(5):576-83. PubMed ID: 24872209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.
    Spence R; Mandagere A; Harrison B; Dufton C; Boinpally R
    J Pharm Sci; 2009 Dec; 98(12):4962-74. PubMed ID: 19455620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.